SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Max Fletcher who wrote (53637)6/6/2006 4:52:08 PM
From: Stuki  Read Replies (1) of 120406
 
AEMD Nice to read a down to earth and realistic comment from the CEO. It is hard to imagine that if their trials in India prove "successful," whatever that may mean in reducing viral loads, that there will not be pressure or a demand here in the USA to rush trials for Hep B&C and Aids or perhaps for "compassionate use" status.. What reducing viral loads means and does the body's immune system then really have a better chance to fight back or to take over is an interesting question. Would repeated Hemopurifier treatments spread over time continue to reduce the viral load and give the body or drugs a chance to keep these illnesses in check or in maintenance status as is diabetes, is another question.
It is interesting that according to the article, some of these questions will be answered by 2007. Not a long time to wait in the bio tech world, especially for a stock at this price with what seems like to me, a great potential.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News